SUMMARY
Provides comprehensive understanding and unprecedented access to the merger and acquisition deals and agreements entered into by the worlds leading healthcare companies during 2012
DESCRIPTION
The Merger and Acquisition Yearbook 2013 report series provides comprehensive understanding and unprecedented access to the M&A deals and agreements entered into by the worlds leading healthcare companies during 2012.
Using these reports, dealmakers will effectively and efficiently gain insight into the M&A activities of the past year. The report series allows you to view all the partnering and alliances deals announced worldwide.
The initial chapters of this report provide an orientation of 2012’s M&A dealmaking and business activities.
Chapter 1 provides an overview of the trends in M&A dealmaking during 2012.
Chapter 2 provides a review of the leading M&A deals during 2012. Deals are listed by headline value, signed by bigpharma and bigbiotech, and most active biopharma. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.
Chapter 3 provides a comprehensive listing of the top 50 bigpharma companies with a brief summary followed by a comprehensive listing of 2012 M&A deals, as well as contract documents available in the public domain. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.
Chapter 4 provides a comprehensive directory of all M&A deals announced during 2012.The chapter is organized by company A-Z. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.
The report series also includes numerous tables and figures that illustrate the trends and activities in bigpharma M&A dealmaking during 2012.
In conclusion, this report provides everything a prospective M&A dealmaker needs to know about partnering in the research, development and commercialization of technologies and products during 2012.
BENEFITS
KEY BENEFITS
Merger and Acquisition Yearbook 2013 series provides the reader with the following key benefits:
Merger and Acquisition Yearbook 2013 series is intended to provide the reader with an in-depth understanding and access to M&A trends and structure of deals entered into by leading companies worldwide.
Merger and Acquisition Yearbook 2013 includes:
Provides comprehensive understanding and unprecedented access to the merger and acquisition deals and agreements entered into by the worlds leading healthcare companies during 2012
DESCRIPTION
The Merger and Acquisition Yearbook 2013 report series provides comprehensive understanding and unprecedented access to the M&A deals and agreements entered into by the worlds leading healthcare companies during 2012.
Using these reports, dealmakers will effectively and efficiently gain insight into the M&A activities of the past year. The report series allows you to view all the partnering and alliances deals announced worldwide.
The initial chapters of this report provide an orientation of 2012’s M&A dealmaking and business activities.
Chapter 1 provides an overview of the trends in M&A dealmaking during 2012.
Chapter 2 provides a review of the leading M&A deals during 2012. Deals are listed by headline value, signed by bigpharma and bigbiotech, and most active biopharma. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.
Chapter 3 provides a comprehensive listing of the top 50 bigpharma companies with a brief summary followed by a comprehensive listing of 2012 M&A deals, as well as contract documents available in the public domain. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.
Chapter 4 provides a comprehensive directory of all M&A deals announced during 2012.The chapter is organized by company A-Z. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.
The report series also includes numerous tables and figures that illustrate the trends and activities in bigpharma M&A dealmaking during 2012.
In conclusion, this report provides everything a prospective M&A dealmaker needs to know about partnering in the research, development and commercialization of technologies and products during 2012.
BENEFITS
KEY BENEFITS
Merger and Acquisition Yearbook 2013 series provides the reader with the following key benefits:
- In-depth understanding of recent M&A dealmaking trends during 2012
- Comprehensive access to all M&A deals entered into by the world’s biopharma companies during 2012
- Detailed access to actual M&A deals and contracts entered into by the leading fifty bigpharma companies
- Understand the key M&A deal terms companies have agreed in previous deals
- Undertake due diligence to assess suitability of your proposed deal terms for partner companies
Merger and Acquisition Yearbook 2013 series is intended to provide the reader with an in-depth understanding and access to M&A trends and structure of deals entered into by leading companies worldwide.
Merger and Acquisition Yearbook 2013 includes:
- Trends in dealmaking in the biopharma industry during 2012
- Comprehensive directory of M&A deals in 2012
- Links to online access to all deals and alliances
- The leading M&A deals by value in 2012
- Most active M&A dealmakers during 2012
- Company A-Z
- Headline value
EXECUTIVE SUMMARY
CHAPTER 1 – TRENDS IN M&A DEALMAKING DURING 2012
1.1. Bigpharma dealmaking activity
CHAPTER 2 – LEADING M&A DEALS DURING 2012
2.1. Introduction
2.2. Top deals by value during 2012
CHAPTER 3 – BIGPHARMA M&A DEALS DURING 2012
3.1. Introduction
3.2. How to use bigpharma M&A deals
3.3. Bigpharma M&A company profiles for 2012
Abbott
Actavis
Actelion
Allergan
Amgen
Aspen Pharmacare
Astellas
AstraZeneca
Baxter International
Bayer
Biogen Idec
Boehringer Ingelheim
Bristol-Myers Squibb
Celgene
CSL
Daiichi Sankyo
Dainippon Sumitomo
Eisai
Eli Lilly
Endo Pharmaceuticals
Forest Laboratories
Galderma
Gilead Sciences
GlaxoSmithKline
Grifols
Hospira
Johnson & Johnson
Kyowa Hakko Kirin
Lundbeck
Menarini
Merck & Co
Merck KGaA
Mitsubishi Tanabe
Novartis
Novo Nordisk
Otsuka
Pfizer
Purdue
Roche
Sanofi
Servier
Shionogi
Shire
Takeda
Teva
Valeant
Warner Chilcott
Watson
CHAPTER 4 – M&A DEALS DIRECTORY 2012
4.1. Introduction
4.2. Company A-Z
ABOUT WILDWOOD VENTURES
Current Partnering
Current Agreements
Current Reports
Recent titles from CurrentPartnering
Order Form – Reports
TABLE OF FIGURES
Figure 1: Bigpharma – top 50 – January to December 2012
Figure 2: Bigpharma deal frequency – 2012
CHAPTER 1 – TRENDS IN M&A DEALMAKING DURING 2012
1.1. Bigpharma dealmaking activity
CHAPTER 2 – LEADING M&A DEALS DURING 2012
2.1. Introduction
2.2. Top deals by value during 2012
CHAPTER 3 – BIGPHARMA M&A DEALS DURING 2012
3.1. Introduction
3.2. How to use bigpharma M&A deals
3.3. Bigpharma M&A company profiles for 2012
Abbott
Actavis
Actelion
Allergan
Amgen
Aspen Pharmacare
Astellas
AstraZeneca
Baxter International
Bayer
Biogen Idec
Boehringer Ingelheim
Bristol-Myers Squibb
Celgene
CSL
Daiichi Sankyo
Dainippon Sumitomo
Eisai
Eli Lilly
Endo Pharmaceuticals
Forest Laboratories
Galderma
Gilead Sciences
GlaxoSmithKline
Grifols
Hospira
Johnson & Johnson
Kyowa Hakko Kirin
Lundbeck
Menarini
Merck & Co
Merck KGaA
Mitsubishi Tanabe
Novartis
Novo Nordisk
Otsuka
Pfizer
Purdue
Roche
Sanofi
Servier
Shionogi
Shire
Takeda
Teva
Valeant
Warner Chilcott
Watson
CHAPTER 4 – M&A DEALS DIRECTORY 2012
4.1. Introduction
4.2. Company A-Z
ABOUT WILDWOOD VENTURES
Current Partnering
Current Agreements
Current Reports
Recent titles from CurrentPartnering
Order Form – Reports
TABLE OF FIGURES
Figure 1: Bigpharma – top 50 – January to December 2012
Figure 2: Bigpharma deal frequency – 2012
